In a significant development affecting the biotech industry, WuXi AppTec, a leading Chinese manufacturing company, has reported a revenue decline for the first half of 2024. This downward trend coincides with growing concerns about the impending BIOSECURE Act, which aims to restrict U.S.
September 27, 2024
The biopharma sector is at an inflection point as the United States grapples with concerns about China's influence and potential risks posed by collaborations with Chinese military medical institutions. A legislative measure known as the BIOSECURE Act aims to address these apprehensions,
August 22, 2024
The introduction of the BIOSECURE Act marks a significant moment in U.S. legislative history, specifically targeting the intersection of national security and biotechnology. This proposed legislation aims to halt federal contracts with Chinese biotech firms, citing potential national security
July 10, 2024
The proposed BIOSECURE Act stands poised to significantly alter the landscape of U.S.-China biopharma partnerships by addressing national security concerns through restrictive measures. Specifically, the act aims to block certain Chinese biotech equipment and service providers from the U.S. market.
July 3, 2024
Recent actions by U.S. House lawmakers have cast a spotlight on GenScript, a Chinese Contract Development and Manufacturing Organization (CDMO), and its cell therapy division, Legend Biotech, amidst concerns of potential Chinese Communist Party (CCP) influence within the American biotech realm.
June 6, 2024
Within the dynamic landscape of the Contract Development and Manufacturing Organization (CDMO) industry, strategic alliances are becoming increasingly crucial. The latest collaboration between Japan's AGC Biologics and the Netherlands-based BioConnection illustrates this point poignantly. They
May 16, 2024
